Baird Financial Group
NBIX icon

Baird Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

Baird Financial Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.08M Sell
38,589
-3,616
-9% -$480K 0.01% 734
2025
Q4 		$5.99M Sell
42,205
-4,756
-10% -$689K 0.01% 687
2025
Q3 		$6.59M Sell
46,961
-6,433
-12% -$872K 0.01% 655
2025
Q2 		$6.71M Sell
53,394
-4,426
-8% -$508K 0.01% 625
2025
Q1 		$6.39M Buy
57,820
+3,103
+6% +$393K 0.01% 603
2024
Q4 		$7.47M Buy
54,717
+24,657
+82% +$3.05M 0.01% 574
2024
Q3 		$3.46M Sell
30,060
-38,906
-56% -$5.33M 0.01% 802
2024
Q2 		$9.49M Buy
68,966
+36,799
+114% +$5.05M 0.02% 496
2024
Q1 		$4.44M Buy
32,167
+6,582
+26% +$899K 0.01% 699
2023
Q4 		$3.37M Sell
25,585
-837
-3% -$96.3K 0.01% 780
2023
Q3 		$2.97M Buy
26,422
+178
+0.7% +$18.7K 0.01% 788
2023
Q2 		$2.47M Buy
26,244
+13,710
+109% +$1.34M 0.01% 844
2023
Q1 		$1.27M Sell
12,534
-4,938
-28% -$514K ﹤0.01% 1029
2022
Q4 		$2.09M Buy
+17,472
New +$2.05M 0.01% 856
2022
Q1 		– Sell
-3,460
Closed -$295K – 1892
2021
Q4 		$295K Hold
3,460
– – ﹤0.01% 1681
2021
Q3 		$332K Hold
3,460
– – ﹤0.01% 1631
2021
Q2 		$337K Sell
3,460
-1,013
-23% -$97.1K ﹤0.01% 1545
2021
Q1 		$435K Buy
+4,473
New +$469K ﹤0.01% 1392

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baird Financial Group's NBIX Position: Q1 2026 in Review

Baird Financial Group reduced its Neurocrine Biosciences (NBIX) stake by 8.6% in Q1 2026, selling an estimated $480K and leaving 38,589 shares worth $5.08M. The position accounts for 0.01% of the portfolio, ranked #734.

Baird Financial Group first reported a position in NBIX in Q1 2021 and has held it in 18 quarters since. The position peaked at $9.49M in Q2 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Baird Financial Group held 38,589 shares of Neurocrine Biosciences worth $5.08M as of Q1 2026.
  • Baird Financial Group sold 3,616 Neurocrine Biosciences shares in Q1 2026, an estimated $480K.
  • Neurocrine Biosciences made up 0.01% of Baird Financial Group's portfolio in Q1 2026, its #734 holding.
  • Baird Financial Group first reported a position in Neurocrine Biosciences in Q1 2021 and has held it in 18 quarters since.
  • Baird Financial Group's Neurocrine Biosciences position peaked at $9.49M in Q2 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Baird Financial Group's 13F filing for Q1 2026, filed 14 May 2026.